

Press Release Frasne,
September 16, 2026

micronora Awards 2026: A Golden Micron for the anti-metastasis microfluidic implant developed by DEM GY Frasne and IBM M

Winner in the “Microtechnical Components & Subassemblies” category, the CAPDCM project will be presented at Micronora from September 29 to October 2, 2026, at the DEM GY booth—Hall 2B—booth 401/500.

DEM GY Frasne (Doubs), a specialist in the Micro-injection molding of ultra-precise parts made of engineering and high-performance polymers for the medical sector, and IBMM (*Max M ousseron Institute of Biomolecules – [CNRS](#), [University of Montpellier](#), [ENSCM](#)), announce that the CAPDCM project has been awarded a Micron d’Or in the “Microtechnical Components & Subassemblies” category. This implantable medical device, designed to capture circulating tumor cells that cause metastases, is being developed with support from the [“Companies and Campus”](#) program

" at the University of Montpellier, as part of the [Montpellier University Innovation Hub](#).

PRESS INVITATION – MICRONORA 2026


Micropolis Besançon – September 29 to October 2, 2026 – DEM GY, Hall 2B – Booth 401/500

The CAPDCM microfluidic device, winner of a Micron d’Or award, will be showcased at the booth. Interviews with the teams from DEM GY Frasne, DEM GY Group, and the

CAPDCM project leaders can be arranged upon request during the trade show.



CAPDCM microfluidic implant—assembled shells designed to capture tumor cells.



Two halves of the microfluidic implant and a top view of one half with a scale.

A “Micron d’Or” to highlight the passage of research to industrialization

Awarded to the CAPDCM project in the “Microtechnical Components & Subassemblies” category, this Micron d’Or highlights an innovation at the intersection of microtechnology and MedTech.

For DEMGY Frasn , this distinction highlights the company’s ability to transform a concept derived from academic research into an industrially viable micro-engineering component by leveraging expertise in tooling design, Micro-injection molding, assembly, and quality control.

It also highlights the synergy between the scientific expertise of IBM M and the industrial know-how of DEMGY Frasn , which is essential for navigating the various stages leading from a research prototype to a future medical device ready for industrial production.



Robotic production cell in an ISO 7 cleanroom.

Source: Ludovic Godard for DEMGY Group

10 μ m microtechnology addressing a major medical challenge

The device is designed to mechanically attract and capture residual tumor cells following the removal of the primary tumor. Developed by the F15 team at IBM M, the concept combines an alginate matrix designed to release a chemoattractant capable of attracting tumor cells, while their capture is ensured by unidirectional micro-harpoons that allow the cells to pass in one direction while preventing them from flowing back.

DEM GY Frasne is responsible for the design and manufacture of the tooling, plastic injection molding, and assembly of the two shells. The main technical challenges involve:

- the fabrication of 10 μm microstructures and the reproducibility of the harpoon shapes arranged every 2° over 360° ;
- control of injection molding parameters to ensure complete filling of the structures, without tearing or filling gaps;
- the final seal between the two shells to ensure the device functions properly.

To meet these requirements, DEM GY Frasne designed a mold capable of producing these geometries with micrometer-level precision and developed an injection molding process to ensure their consistent reproduction. The harpoon-shaped features, which are difficult to achieve through conventional Micro-machining at this scale, are produced using laser engraving.

Dedicated to the medical market, the DEM GY Frasne facility operates entirely in ISO 7 and ISO 8 cleanrooms and manages the entire value chain: design, tooling, injection molding, assembly, quality control, and packaging.

“CAPDCM illustrates the ability of French academic research to make “to foster disruptive innovations with a significant medical impact,” emphasizes Jean-Marie Ramirez.

He is an associate professor at the University of Montpellier, director of the F15 “Oncotherapy and Oncopharmacology” team at IBM M, and the project’s scientific coordinator.

Through this project, DEM GY Group is continuing to expand its activities in advanced medical technologies by leveraging its expertise in high-performance polymers, precision processes, and controlled environments.

A MedTech project with strong industrial and clinical potential

The identified development objectives include:

- 3,600 units produced in the first year;
- up to 36,000 units eventually on the French market;

The project is protected by several patents and could, in the medium term, lead to:

- regulatory approvals;
- collaborations with hospitals;
- gradual industrialization on a European scale.

This recognition comes at a key stage of the project, which is currently in the preclinical validation phase, with initial in vivo proof of concept expected before the end of 2026.

A project supported by the University of Montpellier

The “Companies and Campus” program, a flagship initiative of the University of Montpellier and the University Innovation Hub, provides financial support for collaborative research projects between laboratories and private Partners to strengthen technology transfer and mobility between public and private stakeholders. It funds innovative projects with grants ranging from €10,000 to €50,000. Since 2018, 16 rounds of funding have supported 63 winning projects and allocated more than €2.5 million to support innovation. This program fosters the creation of lasting collaborations between public research and economic stakeholders to boost the appeal and commercialization of innovations.

Led by the University of Montpellier as the lead partner, the University Innovation Hub brings together 14 founding members from academia, research, and innovation around a common goal: to encourage partnerships between research and the socio-economic sector, develop technology transfer, and stimulate the creation of innovative companies in the Montpellier region.



www.umontpellier.fr/pui

About DEM GY GROUP

DEM GY GROUP is an international mid-sized technology company specializing in weight reduction through its high-performance plastic and Composite solutions, which are lighter than metal.

In 2004, Pierre-Jean Leduc took over Dedienne (founded in 1947) through a management buyout (MBO*) as President & CEO, after having led and developed the company for 13 years, to create DEM GY GROUP.

Since then, DEM GY GROUP has experienced continuous growth based on innovation, international expansion, and technological advancement through both organic and external growth.

Following its latest acquisition in the U.S. in March 2025, the group has become the global leader in plastic and Composite components for aircraft cabin interiors, serving as a Tier 1 supplier to Airbus, Boeing, and the largest aerospace equipment manufacturers.

With operations in France (4 sites, including its headquarters in Saint-Aubin-sur-Gaillon, Normandy), Germany (2 sites), Romania (2 sites), and the United States (2 sites), the Group also has 3 R&D centers and 2 sales offices in England and Israel. In 2025, DEM GY GROUP generated revenue of €125 million, 7% of which was invested in R&D and industrial equipment, and employed 910 people. DEM GY GROUP aims to reach €200 million in revenue and employ 1,400 people by 2030.

*Management Buyout

www.demgy.com

Circular Multiplasturgy®: An Integrated Model Serving Cutting-Edge Industries

DEM GY structures its development around Circular Multiplasturgy®, an integrated model combining engineering, materials and processes, co-design, and multi-technology industrialization under a single Partner, with operations in Europe and the U.S.

By bringing together 15 technologies for processing high-performance polymers and composites, DEM GY supports the most demanding sectors by from the early stages of projects through to series production, and has established itself as a one-stop shop for any weight-reduction solution using high-performance plastics and composites.

Commitment to the low-carbon transition

DEM GY is involved in the ACT (Assessing Low Carbon Transition) project and is leading the ACT'Eure initiative locally, notably through the commissioning of its first solar power plant in Normandy. Thanks to this initiative, DEM GY now has carbon footprint assessments for its sites in France, as well as its decarbonization roadmaps for 2030 and 2050.



DEM GY is a member of the Coq Vert community, a group of business leaders who are convinced of the need to take action and are already committed to the ecological and energy transition.



DEM GY is a founding member and ambassador of the French Fab.

[Download visuals](#)

Press contact: Cécile Ponchel - cecile.ponchel@sotchi.fr - 0603020232